NEW YORK, Dec. 7 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) today lists the common stock of Xcorporeal, Inc. under the ticker symbol XCR.
Xcorporeal, Inc. is a medical device company developing an innovative extra-corporeal platform technology that may be used in devices to replace the function of various human organs. The platform will lead to three initial products; a device for home hemodialysis, another device for hospital Renal Replacement Therapy (RRT) and the Wearable Artificial Kidney (WAK) for continuous ambulatory hemodialysis. These devices will seek to provide patients with improved, efficient and cost effective therapy. The RRT markets represent multibillion dollar opportunities.
“We are pleased to welcome Xcorporeal, Inc. to the American Stock Exchange,” said Neal Wolkoff, Chairman and CEO of Amex. “We look forward to working with Xcorporeal and building strong relationships within the investment community to enhance their growth in the marketplace.”
The specialist for Xcorporeal, Inc. is Cohen Specialist LLC. For further information on XCR and other Amex-listed companies, please visit www.amex.com.
About American Stock Exchange
The American Stock Exchange(R) (Amex(R)) offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 379 ETFs to date. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. For more information, please visit www.amex.com.
CONTACT: Media, Catherine Chantharaj of American Stock Exchange,
+1-212-306-1689, catherine.chantharaj@amex.com
Web site: http://www.amex.com//
